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Summary A partially purified fraction of the water soluble photosensitive dye sulphonated aluminium
phthalocyanine (AlSPc) was encapsulated in liposomes which were then linked to a targeting monoclonal
antibody 791T/36 using a heterobifunctional linking agent. The photocytotoxic effects of the liposomes were
determined on two cell lines bearing an antigen with which the targeting antibody binds: 791T, an
osteosarcoma and C170, a colorectal carcinoma; and a control cell line not bearing the antigen; DW-BCL, an
Epstein-Barr virus immortalised B-cell line. Antibody dependent cytotoxicity was observed in 791T and C170
cells and was proportional to the number of antigens on the cells, the AlSPc concentration and the time of
exposure to activating red light. No significant toxicity was seen using untargeted liposomes, control cells or
free AlSPc fraction under similar conditions. Targeted cells and controls kept in the dark also showed no
significant toxicity. A possible mechanism of action is postulated and simple adaptations which demonstrate
the versatility of the model are discussed. Some suggestions as to the clinical situations to which this system
might be applied in the form of photodynamic therapy (PDT) are made.
Cancer chemotherapy depends on agents which are selective
in their activity against malignant cells, and progress results
from the deployment of new compounds with increased
selectivity or new ways of administering existing agents.
Chemotherapeutic agents are largely phase or cycle
specific and therefore inactive against cells in the resting
phase of the cell cycle. Drugs would be more effective if they
were independent of cell growth whilst maintaining
specificity to the tumour cells. Antibody targeting of
liposome encapsulated drugs is highly specific (Gray et al.,
1988) but their cytotoxicity is limited by cell cycle kinetics
and the rate of internalisation of the liposomes. This varies
widely depending on the target antigen, liposome size and
composition and in some cells despite excellent liposome
attachment no toxicity occurs (Machy et al., 1982). However,
a liposome encapsulated agent which does not require
internalisation but can exert its cytotoxic action from the cell
surface would be independent of this variable. If in addition
it were toxic to resting tumour cells a more universal and
effective drug targeting system could be envisaged.
Phthalocyanine dyes are such a class of compounds
(reviewed by Spikes, 1986), whose cytotoxic action is thought
to be primarily by generation of free radical singlet oxygen
on exposure to light of specific wavelengths (Brasseur et al.,
1985). Sulphonated aluminium phthalocyanine (AlSPc) was
encapsulated in liposomes bearing the monoclonal antibody
791T/36 and tested for photocytotoxicity against an
osteosarcoma cell line 791T. This demonstrated rapid and
highly specific cell killing in conditions which favoured the
prevention of liposome internalisation by the cells.
Materials and methods
Cells
The phototoxicity of AISPc liposomes was tested in an
osteosarcoma cell line with targeting antibody a mouse
monoclonal 79IT/36 (subclass IgG 2b), raised against an
epitope expressed on this line. Both cell line and antibody
are well characterised and documented (Garnett et al., 1983;
Perkins et al., 1985; Roe et al., 1985). 791T/36 also binds
with a colorectal carcinoma cell line C170 and other cells
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(Embleton et al., 1981). Cell lines 791T, C170 and the
antibody 791T/36 were supplied by Prof. R.W. Baldwin of
CRC Nottingham University.
Control cells were DW-BCL, an Epstein-Barr virus (EBV)
immortalised polyclonal B-cell line derived from an
individual seronegative to EBV. DW-BCL did not express an
epitope which bound 791T/36 (as shown by indirect
immunofluorescence).
Purification of AlSPc
AlSPc powder (Ciba-Geigy) dissolved in distilled water was
streaked onto preparative TLC plates (20 x 20 cm 1,000gm
Whatman PLK-5 silica gel plates) which were developed in a
mixture of acetone, water, n-butanol, 5% ammonium
hydroxide (13:15:58:13). The most polar fraction, nearest
the origin (Rf= 0.13), was scraped off, eluted in distilled
water, filtered and freeze-dried to a powder. This was
rechromatographed to give one line in the same system.
Preparation of liposomes
Small unilamellar liposomes (SUV) were prepared by probe
ultrasonication and coupled to antibody according to the
methyod of Barbet et al. (1981). Purified AlSPc was
encapsulated at 2mgml-1 in Hepes-buffer at pH 7.4 (10 mM
Hepes, 145 mM NaCl). 791T/36 antibody, 1.5 mg, was
labelled with a trace of 1251, iodinated by the lodogen
method (Pierce). Eighty-five per cent of antibody (as
determined by the radioactive label) was coupled to the
liposomes. The liposomes were sterilised by filtering through
a 0.45pm Flowpore D unit and stored at 4°C until used.
Control liposomes were prepared in an identical way,
encapsulating AlSPc or buffer and either coupled to an
irrelevant protein (in this case a sheep anti-mouse antibody,
SWM), or left without antibody.
Liposomes in these preparations had an average diameter
of 50 nm as measured on electron micrographs. Allowing for
a bilayer width of 4nm and estimating 2,680 phospholipid
molecules per liposome (Wilschut, 1982) after adjusting for
cholesterol content, the number of AlSPc molecules per
liposome was calculated. Two different methods were used
which agreed closely: (a) a calculation based on the volume
of a sphere and the concentration of AlSPc used gave a
value of 59 AlSPc molecules per liposome; (b) measurements
of AlSPc and phospholipid concentrations of prepared
liposomes gave a value of 53 + 9 (s.e.m.) on three different
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liposome preparations. Phospholipid was measured by the
method of Stewart (1980). The agreemnent suggests that the
AISPc was in the aqueous phase of the liposome interior.
Immunofluorescence analysis of cells
Cells in suspension (2 x 105) were incubated at 4°C with a
saturating concentration of 791T/36 antibody for 45min,
washed, then stained with fluorescent liposomes containing
carboxy-fluorescein and coupled to a polyclonal sheep anti-
mouse antibody (Gray et al., 1988) for a further 45min,
washed and analysed on a Fluorescence Activated Cell
Sorter (FACS IV; Beckton and Dickinson).
Experimental
Cells were grown in a monolayer in a growth medium
comprising Eagles minimum essential medium (EMEM:
Gibco) supplemented with 10% fetal calf serum (FCS), and
subdivided at confluence after treatment with 0.25% trypsin
(Sigma) and 0.5% EDTA (Fisons) in EMEM.
For each experiment 1 x 104 cells harvested at confluence
were added to triplicate flat-bottomed wells in culture plates
and incubated at 4°C with liposomes (50pl) for 45 min.
After washing once, growth medium was added and the
plates exposed to red light for variable periods of time, or
kept in the dark. Cells were then incubated in a humidified
atmosphere with 5% CO2 at 37°C for 72 h. Cells were pulsed
during the last 16 h with 3H-leucine (Amersham), harvested
and the radioactivity was counted.
Red light source
The light source was two 15 W fluorescent tubes (Lidam
Scientific) fitted with a red filter (as described by Chan et al.,
1986) which gave peak emissions between 600 and 700 nm,
corresponding to one of the main absorption peaks of
AlSPc. Cells were irradiated at a distance of 7 cm from the
source which gave a light intensity of 1.7 mWcm-2 as
measured by a Coherent 212 Power Meter.
Results
791T, C170 and DW-BCL cells. The liposome/cell
combinations were tested with and without exposure to red
light for 25 min, as shown in the legend to Figure 1. In the
liposome preparation added to cells the final AlSPc
concentration was 2.5 ugml-1 (which is the amount of
AlSPc which would be present in the incubation volume if
the liposomes were lysed) and the antibody concentration
was 10yugml-1.
Results are expressed as the percentage growth of controls
72 h after treatment. The 100% controls were cells incubated
with liposomes containing no AlSPc, but with or without
antibody for targeted and untargeted controls respectively.
Significant differences were determined by unpaired
Student's t tests.
Figure 1 shows that AlSPc photosensitised liposomes are
only toxic to 791T and C170 cancer cells when both
targetted by antibody and exposed to red light (7, 8, 9).
Targeted AlSPc liposomes at 2.5 ugml-1 were less toxic for
C170 cells than for 791T cells (7.9) (PA0.005), but at
4.25 ,ugml-1 (8,9) were equally toxic (no significant
difference). Free AlSPc at concentrations of 2.5 and
25 tgml-1 and all controls showed no significant toxicity
whether irradiated with red light or not.
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Purification of AlSPc
AlSPc was found to be a mixture of isomeric mono, di-, tri-
and tetra-sulphonated forms which yielded many fractions
on TLC, their position depending on their degree of
solubility. A partial purification was performed as described
in Materials and methods in order to give a more uniform
and polar compound which was more suitable for
encapsulating in the aqueous compartment of liposomes than
the original mixture. HPLC of the purified fraction showed
the presence of several peaks and suggested that it was
composed mainly of tetra- and tri-sulphonated AlSPc.
Immunofluorescence analysis of cells
The saturating concentration of 791T/36 antibody was
2pgml-1 and 50ugml-P for 791T and C170 cells
respectively, which suggests different binding kinetics of the
antigen on the different cell types for 791T/36. Indirect
immunofluorescence phenotyping at this antibody
concentration gave 98% of 791T cells positive compared
with 52% of C170 cells. DW-BCL were negative, as were
791T and C170 cells reacted with an irrelevant antibody of
the same subclass. The three cell types were also negative
when incubated with fluorescent liposomes in the absence of
antibody.
Phototoxicity of targeted AlSPc-liposomes
Targeted and untargeted AlSPc liposomes, AlSPc lipopsomes
coupled to an irrelevant antibody and free AlSPc in the
presence of buffer containing liposomes were incubated with
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Figure 1 Effect of targeted and untargeted liposomes and free
AlSPc on three different cell lines (n=5 different experiments
with triplicates for each point). Error bars are standard errors of
the mean (s.e.m.) Cells were treated as described in the text and
according to the following protocol: (A) cells not carrying the
appropriate surface antigen, (1) targeted AlSPc-SUV with 791T/
36 Ab attached + DW-BCL; (B) untargeted AlSPc-liposomes, (2)
untargeted AlSPc-SUV with irrelevent Ab attached + 791T, (3)
untargeted AlSPc-SUV with no attached Ab + C170, (4) untar-
geted AISPc-SUV with no attached Ab + 791T; (C) free AlSPc,
(5) free AlSPc (2.5Mgml-1) + buffer-SUV + 791T, (6) free AISPc
(25pgml-1) + buffer-SUV + 791T; (D)targetedAlSPc-liposomes,
(7) targeted AlSPc-SUV (2.5pgml-') with 791T/36 Ab atta-
ched + C170, (8) targeted AlSPc-SUV (4.5pgml-1) with 791T/36
Ab attached + C170, (9) targeted AlSPc-SUV (2.5 pgml -1) with
791T/36 Ab attached + 791T.368 J. MORGAN et al.
Dose response to light exposure
791T cells were set up with controls as previously described
but this time the red light irradiation varied from 0 to
25 min. Figure 2 shows a typical dose-response curve in
which increasing exposure time to red light caused increasing
toxicity up to a maximum (25 min). There was no effect
on untargeted controls.
Antibody/AISPc dose response
A further dose-response curve was set up but this time the
variable was the reduction in the numbers of liposomes by
serial dilution. For each dilution both the amount of
antibody and AlSPc change proportionately since they are
directly dependent on each other and the number of
liposomes. The dose-response curve in Figure 3 shows that
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Figure 2 Effect of increasing light exposure time on phototoxi-
city of AlSPc liposomes to 791T cells treated as described in the
text (n=3 different experiments with triplicates for each point).
Untargeted liposomes at 2.5 pgml-1 AISPc final concentration
(Ml). Liposomes targeted with 791T/36 MoAb at 2.5 jgml-P
AlSPc final concentration (U).
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Figure 3 Liposome dose-response curves. Effect of increasing
dilution of AlSPc liposomes on 791T cells, treated as described in
the text (n =3 different experiments with triplicates at each
point). Liposomes targeted with 791T/36 MoAb at 6 gml-1
AlSPc (neat liposomes) (*); 3 jg ml-I AlSPc (half the number of
liposomes) (O); 1.5pgml-P AlSPc (quarter the number of lipo-
somes) (-); 0.75pgml-P AlSPc (eighth the number of lipo-
somes) (O). Liposomes targeted with an irrelevant antibody
(sheep anti-mouse) at 6.ugml-1 AlSPc (neat liposomes) (El).
increasing dilution of liposomes results in decreasing
phototoxicity for a fixed time exposure.
Discussion
AlSPc and other phthalocyanines have been reported to have
tumour localising properties in their own right (Rosseau et
al., 1983; Tralau et al., 1987; Singer et al., 1987, 1988). This
is probably mediated by the lipophilicity of the less polar
fractions of AlSPc such as the di- and mono-sulphonated
forms (Paquette et al., 1988). While this may facilitate
uptake into tumour cells there is also the potential for
uptake by normal cells and hence damage on illumination. It
was therefore thought that encapsulating the dye in lipo-
somes and directing them to tumour cells with antibodies
might decrease the non-specific uptake by normal cells as
well as improving the tumour localising properties as a result
of antibody targeting, thereby increasing the therapeutic
ratio.
Lipophilic contaminants found in other compounds such
as carboxyfluorescein have been found to concentrate in and
perturb liposomal membranes and to transfer more rapidly
to cells than purified carboxyfluorescein (Ralston et al.,
1981). In line with this it has been found that liposomes
prepared with unfractionated AlSPc were very sticky and
bound to cells non-specifically, thus decreasing the differen-
tial toxicity between targeted cells and untargeted controls.
This effect was slightly reduced by first passing the dye down
an LH 20 column which removed the most lipophilic compo-
nents such as the di, mono and unsulphonated phthalocya-
nine molecules (personal observations). For this reason the
most polar fraction of AlSPc was selected for encapsulation
in liposomes. Another source of non-specific interaction of
AlSPc and cells lies in its avid binding to protein (Ben-Hur
& Rosenthal, 1985a, b; Chan et al., 1986; personal obser-
vations). This avidity would pose problems were AlSPc to be
bound directly to a monoclonal antibody. We have observed
(for example) 5-10% mole for mole non-specific binding of
AlSPc to human serum albumin, depending on pH(7-9).
Sequestration of AlSPc in liposomes has the potential for
preventing it binding non-specifically to proteins present in
the medium and on the surface of cells. Furthermore,
liposome delivery allows a larger number of AlSPc molecules
to be directed to each binding site on the cell. Roberts et al.
(1987) coupled only two porphyrin molecules per antibody
molecule, whereas our liposomes contained an average of 53
molecules of AlSPc, an amplification of more than 25 times.
The results of this paper show that AlSPc can be success-
fully encapsulated in liposomes and targeted against cells
without non-specific phototoxicity, and that the degree of
toxicity is dependent on the dose of both light and photo-
sensitiser. The treatment is rapid and requires only 45min
for antibody binding plus up to 25min for light treatment.
In any targeting system there is the possibility of unwanted
non-specific effects. These have been minimised in the
present system by a number of factors. Firstly the liposomes
are reasonably stable (20% leakage of contents after 4
months storage at 4°C) so there is little leakage into the
medium. Secondly, once the light source is removed there is
no further activation of the dye and any cell damage will be
due to the effects of the toxic species already generated.
Thirdly, even if some dye does escape from liposomes, this
fraction of AlSPc which has been selected is not easily taken
up into cells due to its polar nature. No light mediated
toxicity was produced in 791T cells by free AlSPc even at
ten-fold the concentration used in targeted liposomes
(Figure 1).
For effective cytotoxicity, previous classes of drugs have
needed to gain access to the cell interior, whether presented
in liposomes (e.g. methotrexate) or attached to the antibody
as an immunotoxin (e.g. ricin). The Ag/Ab/drug complex
must be endocytosed for effective action. However, not all
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Iantigens or receptors are internalised and some are shed
from the surface and are thus unsuitable for drug delivery.
AlSPc and other photosensitisers, for example chlorin e6
(Oseroff et al., 1986) do not necessarily need internalisation
to be effective cytotoxic agents. In the present experiments
conditions were used (incubtion at 4°C) that would not
favour the kinetics of endocytosis or antigen shedding;
therefore AlSPc would not gain access to the interior of the
cell. The effect of targeting the AlSPc in liposomes therefore
seems to be to concentrate the photosensitiser in sufficient
proximity to the cell for it to have a cytotoxic action after
light activation. It is possible that the liposome membrane is
destroyed in the process. The main target sites for the active
entity are probably the cell membrane and nearby cytoplas-
mic components which are attacked by singlet oxygen after
its generation and diffusion from the lysed liposome. Singlet
oxygen causes damage to cells by oxidation of biological
molecules important for the integrity and functioning of the
cells such as phospholipids, cholesterol, amino acids and
nucleic acids (Grossweiner, 1981). The postulated mechanism
of action is thus similar to the lytic action of the comple-
ment system on the integrity of the cell membrane, and
therefore, unlike many cytotoxic drugs AlSPc is able to
destroy resting or slow growing cancer cells as well as
actively dividing cells, which suggests it has the potential of
a potent anticancer agent.
The phototoxic action of AlSPc is very rapid compared
with drugs which must be internalised to cause toxicity.
After 4h incubation of 791T cells at 37°C only 30% of
791T/36 on the surface is internalised under saturating
conditions (Huehns, 1986). Any drug attached to the anti-
body is likely to take a similar time to gain access to the cell.
By comparison, production of free radicals on illumination
of 791T/36 bound liposomes containing AlSPc is practically
instantaneous.
It is uncertain to what degree singlet oxygen will be able
to damage zadjacent cells. The mean distance a singlet oxygen
molecule can diffuse during its lifetime has been quoted as
1,000 A (Lindig & Rodgers, 1981; Grossweiner, 1981). It has
been suggested that this is too short a distance for diffusion
to neighbouring cells (Yemul et al., 1987), though that would
depend on how close the cells are positioned. Certainly in
the present experiments the conditions are such that the cells
are remote from each other and there is little possibility of
singlet oxygen diffusion from one cell to another. Further-
more, Sonada et al. (1987) provide evidence that exogenous
AlSPc is not responsible for haemolysis of red blood cells,
presumably because the active singlet oxygen was not cap-
able of diffusing close enough at sufficient concentration,
while bound AlSPc haemolysed the cells. However, the
opposite was suggested by Oseroff et al. (1986), that the
diffusion distance of singlet oxygen may be sufficient to
cause destruction of adjacent cells, and that shed complexes
may still be effective provided they remain close. Our
experiments confirm that AlSPc in liposomes bound to cells
by antibody causes phototoxicity while free AISPc does not.
In the present experiments a monoclonal antibody is used
to target liposomes directly to the cells. However, for some
cell types, perhaps expressing low density antigens, a mixture
of such antibodies rather than a single one might be more
suitable for attaining maximum cell kill. In this situation an
indirect method of targeting is envisaged, in which cocktails
of mouse monoclonal antibodies attach to the cells and the
phototoxic liposome is coupled to polyclonal anti-mouse
antibody which will bind to all the monoclonal antibodies.
Previously, protein A was used for indirect targeting of
liposomes as described by Gray et at. (1988), but use of an
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anti-mouse antibody would be more versatile since it ensures
binding to all Ig subclasses whereas protein A has restricted
binding at physiological pH. Of course, where rat or any
other species of monoclonal antibody are used the appropri-
ate anti-species antibody must be attached to the liposome.
Most drug-Ab conjugates or liposome-Ab targeted drugs
have had reasonable success as cytotoxic agents in vitro, but
not in vivo, due to rapid uptake by the reticulo endothelial
system, which prevents the drug reaching the target
(Weinstein, 1984), though some success has been achieved by
exploiting the uptake of phthalocyanine containing lipo-
somes by low density lipoproteins (LDL), and their subse-
quent delivery to tumour tissues with high LDL receptor
expression (Reddi et al., 1987). However, in some situations,
such as treatment of malignancies affecting the body cavities,
for example ovarian carcinoma, where ex vivo manipulations
of cells are involved such as bone marrow transplantation,
or where the affected organ is accessible to instillation, such
as the bladder, they can still have an important role to play.
This is particularly so in conditions where current treatment
is inadequate, such as advanced ovarian carcinoma, or in
autologous bone marrow transplantation (ABMT) where it
would be used for purging as, for example, in multiple
myeloma.
Intraperitoneal treatment of ovarian carcinoma has been
attempted with limited success by administration of chemo-
therapeutic agents at much higher concentrations than would
be given systemically (Richardson et al., 1985). An advan-
tage of such treatment is lower systemic toxicity, but there
are local side effects due to free cytotoxic drug. With our
liposome system tumour cells would be targeted by mono-
clonal antibodies and the normal peritoneum would be
protected from non-specific uptake by the insulating effects
of the encapsulating lipid. Intraperitoneal photodynamic
therapy (PDT) of ovarian cancer would be feasible by
i.p. injection of Ab targeted AlSPc liposomes followed by
laser light delivered by quartz fibre for photoactivation.
This technique may also be widely applicable for the ex
vivo purging of residual disease from the bone marrow of
patients undergoing ABMT after high dose chemotherapy or
total body irradiation to eliminate bulk disease. Pharmaco-
logical agents have been used to purge marrow from patients
with lymphoma and leukaemia, but they lack selectivity and
are equally toxic to normal haemopoietic cells (Singer &
Linch, 1987). With the right combination of monoclonal
antibodies it should be possible to target and destroy tumour
cells in bone marrow while sparing the normal haemopoietic
precursor cells necessary for re-engraftment.
Purging is not thought to be necessary for ABMT where
bulk disease can be satisfactorily eliminated and there is no
detectable disease in the marrow. However, where there is
marked infiltration of tumour cells in the bone marrow, as
in multiple myeloma, then purging with antibody targeted
AlSPc liposomes might offer a better chance of recovery
without relapse.
Finally, it has been shown that monoclonal antibodies
(produced against antigens of human bladder transitional
cell carcinoma) bind preferentially to tumour rather than
normal mucosa after intravesical injection (Chopin &
deKernion, 1986). Targeting AISPc-liposomes with such
antibodies could provide an alternative route for treatment
of bladder tumours.
Thanks to Russel Svenson of the Royal Institution, London for
advice on the purification of AlSPc and for running the HPLC. This
work was supported by a grant from Bloomsbury Health Authority.
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